Cargando…

Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

The current role of chemotherapy in pancreatic carcinoma is limited, and progress in the treatment of this disease represents a significant challenge to medical oncology. The most promising drug under study is gemcitabine, a relatively new antimetabolite that represents an attractive candidate for c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neri, B, Cini, G, Doni, L, Fulignati, C, Turrini, M, Pantalone, D, Mini, E, De Luca Cardillo, C, Fioretto, L M, Ribecco, A S, Moretti, R, Scatizzi, M, Zocchi, G, Quattrone, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376146/ https://www.ncbi.nlm.nih.gov/pubmed/12189543 http://dx.doi.org/10.1038/sj.bjc.6600482

Ejemplares similares

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
por: Cappuzzo, F, et al.
Publicado: (2004)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Weekly epirubicin in patients with hormone-resistant prostate cancer
por: Petrioli, R, et al.
Publicado: (2002)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
por: Conte, P F, et al.
Publicado: (2005)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
por: Scheithauer, W, et al.
Publicado: (1999)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
por: Twelves, C. J., et al.
Publicado: (1989)

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004)

Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
por: Neri, B, et al.
Publicado: (2007)

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study
por: Frasci, G, et al.
Publicado: (2006)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil
por: Samide, Adriana, et al.
Publicado: (2021)

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
por: Provenzano, Salvatore, et al.
Publicado: (2017)

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
por: Chen, X, et al.
Publicado: (2003)

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas(†)
por: Ramanathan, R. K., et al.
Publicado: (2016)

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
por: Chiorean, E. G., et al.
Publicado: (2016)

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
por: van Putten, J W G, et al.
Publicado: (2000)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas
por: Kong, Dehua, et al.
Publicado: (2022)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2014)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma
por: Ju, Rui-Jun, et al.
Publicado: (2016)

Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
por: Chi, K. H., et al.
Publicado: (1998)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
por: Twelves, C. J., et al.
Publicado: (1992)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
por: Jones, R L, et al.
Publicado: (2009)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_psv95h95gnld8257olqbji5bn9